Floatz logo

Capecitabine

Weight Gain

Oregon Research InstituteSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Weight Gain cohort.

Asset / SponsorPhaseRating
17-beta-estradiol
University of Colorado, Denver
Phase 4BB
Letrozole
Nationwide Children's Hospital
Phase 1CC
METAMIZOLE
Universidad de Sonora
N/AD
DEXKETOPROFEN
Universidad de Sonora
N/AD
NEPENTHE
Universidad de Sonora
N/AD
Olea europaea oil
China Medical University Hospital
N/AD

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →